Little is known about the genetics and biology of chordoma, a rare and aggressive bone tumor. Chordomas occur in approximately one in a million people in the U.S. a year and only five percent of these are in children.
Intra-Cellular on track for another Caplyta label expansion after positive Ph3 depression data
Intra-Cellular Therapies’ Caplyta significantly improved symptoms in a late-stage major depressive disorder trial, marking a step in the drug’s journey to becoming a pipeline-in-a-pill. Atypical
April 17, 2024